Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology

Area of Science:

• Cardiology
• Pharmacology

Background:

• Antithrombotic therapy, combining anticoagulants and antiplatelet agents, is vital in interventional cardiology, especially for acute coronary syndromes (ACS) treated with percutaneous coronary intervention (PCI).
• Increased bleeding risk with current antithrombotic regimens is a significant concern, as bleeding complications correlate with higher risks of ischemic events and mortality.
• Limitations of existing anticoagulants drive the development of novel agents with improved efficacy and reduced bleeding profiles for PCI procedures.

Purpose of the Study:

• To review the pharmacological properties and clinical applications of bivalirudin, a direct thrombin inhibitor (DTI).
• To focus on major clinical trials evaluating bivalirudin in patients undergoing PCI, particularly those with ACS.

Main Methods:

• Review of pharmacological data and clinical trial outcomes for bivalirudin.
• Analysis of bivalirudin's efficacy and safety in patients undergoing PCI.

Main Results:

• Bivalirudin, a synthetic peptide DTI, exhibits predictable pharmacokinetics and favorable properties for anticoagulation during PCI.
• Bivalirudin is approved for routine PCI and for patients with ACS undergoing PCI, demonstrating efficacy in these settings.
• Clinical trials highlight bivalirudin's role in managing thrombosis while addressing bleeding concerns.

Conclusions:

• Bivalirudin represents a significant advancement in antithrombotic therapy for interventional cardiology.
• Its unique properties and clinical trial data support its use in PCI, offering a balance between efficacy and safety.
• Ongoing research and trials continue to define the optimal role of bivalirudin in cardiovascular care.